Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ROMERO FAMILY MEDICINE,LLC

NPI: 1902112956 · ALBUQUERQUE, NM 87109 · Clinic/Center · NPI assigned 08/27/2010

$939K
Total Medicaid Paid
16,890
Total Claims
15,291
Beneficiaries
22
Codes Billed
2018-01
First Month
2024-02
Last Month

Provider Details

Authorized OfficialROMERO, ANGELA (PHYSICIAN)
NPI Enumeration Date08/27/2010

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 3,526 $139K
2019 2,432 $136K
2020 2,364 $150K
2021 2,629 $135K
2022 2,799 $156K
2023 2,784 $188K
2024 356 $35K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 9,240 8,237 $701K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 2,175 2,003 $127K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 501 448 $40K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 426 380 $18K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine 704 691 $13K
90688 824 801 $12K
80305 1,291 1,150 $11K
90460 Immunization administration through 18 years of age via any route, first or only component 196 194 $6K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 26 26 $4K
99394 Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) 24 24 $2K
90686 129 129 $2K
99393 Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) 13 13 $1K
94760 897 783 $379.79
99173 16 16 $308.00
96127 68 65 $232.61
92551 16 16 $156.94
99072 170 148 $13.91
1111F 68 66 $0.00
1126F 48 48 $0.00
1170F 27 27 $0.00
G0008 Administration of influenza virus vaccine 18 13 $0.00
3014F 13 13 $0.00